Vir doses first patient in Phase 1 VIR-5500 expansion trial for metastatic prostate cancer

Reuters04-13 20:08

Vir doses first patient in Phase 1 VIR-5500 expansion trial for metastatic prostate cancer

Vir began enrollment in Phase 1 dose-expansion cohorts for VIR-5500, a PSMA-targeted T-cell engager, following dosing of first patient in metastatic prostate cancer study NCT05997615.
Phase 1 results were already presented at 2026 ASCO Genitourinary Cancers Symposium, supporting a favorable safety profile and early signs of anti-tumor activity.
Expansion cohort will assess whether VIR-5500 can deliver meaningful responses in late-line metastatic castration-resistant prostate cancer.
Combination dose escalation with enzalutamide continues, with first patients in combination expansion cohorts expected over coming months.
Company plans to move into pivotal Phase 3 trials in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260413500942) on April 13, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2627814458?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-13 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627814458","market":"us","top_or_hot":-1,"title":"Vir doses first patient in Phase 1 VIR-5500 expansion trial for metastatic prostate cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vir doses first patient in Phase 1 VIR-5500 expansion trial for metastatic prostate cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Vir began enrollment in Phase 1 dose-expansion cohorts for VIR-5500, a PSMA-targeted T-cell engager, following dosing of first patient in metastatic prostate cancer study NCT05997615.\n        </li>\n<li>\n          Phase 1 results were already presented at 2026 ASCO Genitourinary Cancers Symposium, supporting a favorable safety profile and early signs of anti-tumor activity.\n        </li>\n<li>\n          Expansion cohort will assess whether VIR-5500 can deliver meaningful responses in late-line metastatic castration-resistant prostate cancer.\n        </li>\n<li>\n          Combination dose escalation with enzalutamide continues, with first patients in combination expansion cohorts expected over coming months.\n        </li>\n<li>\n          Company plans to move into pivotal Phase 3 trials in 2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260413500942) on April 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir doses first patient in Phase 1 VIR-5500 expansion trial for metastatic prostate cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir doses first patient in Phase 1 VIR-5500 expansion trial for metastatic prostate cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-04-13 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vir doses first patient in Phase 1 VIR-5500 expansion trial for metastatic prostate cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Vir began enrollment in Phase 1 dose-expansion cohorts for VIR-5500, a PSMA-targeted T-cell engager, following dosing of first patient in metastatic prostate cancer study NCT05997615.\n        </li>\n<li>\n          Phase 1 results were already presented at 2026 ASCO Genitourinary Cancers Symposium, supporting a favorable safety profile and early signs of anti-tumor activity.\n        </li>\n<li>\n          Expansion cohort will assess whether VIR-5500 can deliver meaningful responses in late-line metastatic castration-resistant prostate cancer.\n        </li>\n<li>\n          Combination dose escalation with enzalutamide continues, with first patients in combination expansion cohorts expected over coming months.\n        </li>\n<li>\n          Company plans to move into pivotal Phase 3 trials in 2027.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260413500942) on April 13, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL4GCPLf:1","article_id":"2627814458","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627814458","pubTimestamp":1776082111,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vir began enrollment in Phase 1 dose-expansion cohorts for VIR-5500, a PSMA-targeted T-cell engager, following dosing of first patient in metastatic prostate cancer study NCT05997615.Phase 1 results were already presented at 2026 ASCO Genitourinary Cancers Symposium, supporting a favorable safety profile and early signs of anti-tumor activity.Expansion cohort will assess whether VIR-5500 can deliver meaningful responses in late-line metastatic castration-resistant prostate cancer.Combination dose escalation with enzalutamide continues, with first patients in combination expansion cohorts expected over coming months.Company plans to move into pivotal Phase 3 trials in 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnolog","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","VIR":"Vir Biotechnology, Inc.","BK4139":"生物科技","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念"},"translate_title":"Vir为转移性前列腺癌1期VIR-5500扩展试验中的第一名患者提供剂量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir doses first patient in Phase 1 VIR-5500 expansion trial for metastatic prostate cancer\n    \n\n\n          Vir began enrollment in Phase 1 dose-expansion cohorts for VIR-5500, a PSMA-targeted T-cell engager, following dosing of first patient in metastatic prostate cancer study NCT05997615.\n        \n\n          Phase 1 results were already presented at 2026 ASCO Genitourinary Cancers Symposium, supporting a favorable safety profile and early signs of anti-tumor activity.\n        \n\n          Expansion cohort will assess whether VIR-5500 can deliver meaningful responses in late-line metastatic castration-resistant prostate cancer.\n        \n\n          Combination dose escalation with enzalutamide continues, with first patients in combination expansion cohorts expected over coming months.\n        \n\n          Company plans to move into pivotal Phase 3 trials in 2027.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260413500942) on April 13, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2627814458","isCrawlerRequest":true}